Lazard Freres Gestion S.A.S. Takes $20.31 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Lazard Freres Gestion S.A.S. bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 49,123 shares of the company's stock, valued at approximately $20,309,000. Lazard Freres Gestion S.A.S. owned about 0.06% of IDEXX Laboratories as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Skandinaviska Enskilda Banken AB publ lifted its position in shares of IDEXX Laboratories by 11.2% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 18,913 shares of the company's stock worth $7,806,000 after purchasing an additional 1,900 shares in the last quarter. Erste Asset Management GmbH boosted its stake in shares of IDEXX Laboratories by 17.9% in the 4th quarter. Erste Asset Management GmbH now owns 3,290 shares of the company's stock valued at $1,365,000 after purchasing an additional 500 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of IDEXX Laboratories by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 453 shares of the company's stock worth $187,000 after acquiring an additional 201 shares during the last quarter. Sequoia Financial Advisors LLC grew its holdings in IDEXX Laboratories by 6.2% during the 4th quarter. Sequoia Financial Advisors LLC now owns 1,685 shares of the company's stock worth $697,000 after acquiring an additional 98 shares during the period. Finally, PFG Advisors raised its stake in IDEXX Laboratories by 0.7% during the 4th quarter. PFG Advisors now owns 7,465 shares of the company's stock worth $3,086,000 after buying an additional 50 shares during the period. 87.84% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on IDXX shares. Piper Sandler boosted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Morgan Stanley cut their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Bank of America upped their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Leerink Partners began coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $533.75.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock traded up $7.06 during mid-day trading on Monday, reaching $422.36. 568,503 shares of the stock traded hands, compared to its average volume of 549,374. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The stock has a market capitalization of $34.35 billion, a PE ratio of 39.58, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The business's 50-day moving average is $438.03 and its 200-day moving average is $446.76. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.